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Regeneration of the liver in all mammalian species, including 
man, is a remarkable and extensively studied, but as yet not 
fully understood, physiological phenomenon. 
The most widely investigated aspect is the response of the 
normal liver to partial resection. After partial resection there is a 
lag period and then the liver undergoes a rapid growth spurt as 
evidenced by DNA synthesis. Histopathologically, the remnant 
hepatocytes become larger (hypertrophy) and undergo 
increased mitosis (hyperplasia). Under controlled conditions, 
the timing of the various events is constant in a given species 
but it differs quite markedly from species to species. Once 
regeneration has commenced, the liver mass is very rapidly 
restored to the normal rreresection level and growth then 
stops. This response to livf'f resection is even more remarkable 
when one considers that normal adult liver cells are stable with 
a very slow turnover rate. However, they clearly retain a latent, 
but very potent, capacity for growth. Regrowth after one or 
more liver lobes have been resected is by compensatory 
hyperplasia (and usually hypertrophy) as the missing lobes do 
not regrow; it is the residual liver lobes that increase in size until 
the original liver mass is restored. 
The reduction in liver mass that is caused by damage to liver 
cells by viruses or hepatotoxins (e.g. carbon tetrachloride), and 
the control of regeneration in this setting, has much wider clini-
cal implications than liver regrowth after resection, but has not 
been nearly as extensively studied. 
Although the understanding of liver regeneration has 
advanced considerably, we still do not know what initiates the 
regenerative response once the liver cell mass has been re-
duced, or what causes the liver to stop growing once the origi-
nal size has been attained. Another poorly understood aspect of 
liver cell growth is what causes the normal liver to stop growing 
once adulthood is reached. 
A particularly controversial area is whether there are specific 
factors that switch on or initiate liver regeneration and other 
factors that potentiate regeneration or permit it to occur nor-
mally, or whether both initiation and potentiation are caused by 
the same factor or factors. Recent evidence on potentiation of 
liver regeneration supports the hypothesis that multiple factors 
are involved (1,2). On the other hand, there is no consensus on 
what initiates regeneration nor is there agreement on the site of 
origin of either the initiating and/or the potentiating factor or 
factors (1). 
An understanding of liver regeneration is clearly important in 
the clinical settings of fulminant hepatic failure and after liver 
resection. However, studies of live.r regeneration might even 
provide clues to more fundamental problems, such as the con-
trol of cell growth in general and why this control is lost in 
malignancy. 
THE CONCEPT OF 
HEPATOTROHPIC FACTORS 
This concept was extensively debated during a recent sym-
posium (2). Blood returning from the nonhepatic splanchnic 
organs via the portal venous system specifically influences both 
the morphology and function as well as the regenerative capac-
ity of the liver. The portal blood constituents responsible for 
these effects have been termed portal hepatotrophic factors. 
Most of the in vivo data on these factors has been accumulated 
by depriving all or part of the liver of portal venous return, by 
partial or complete removal of nonhepatic splanchnic viscera or 
by infusing hormones or other substances into either the portal 
or the systemic circulation (1). It is important to separate non-
regenerative hepatotrophic effects (effects on liver morphology 
and function) from the effects of the so-called hepatotrophic 
substances on liver regeneration (1). 
Non-Regenerative Hepatotrophic Effects 
When the liver is deprived of portal blood (creating a porto-
prival state) by portacaval shunting or other technical maneu-
vers, the hepatocytes shrink in size (atrophy). Amongst other 
morphological changes in the liver cells, the most striking and 
specific are depletion and disruption of the rough endoplasmic 
reticulum and reduction in membrane bound polyribosomes. 
All of these changes occur rapidly, being almost complete 
within 4 days, and have been noted in the livers of all speci,es 
studied to date, although the degree may vary. 
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Liver function is similarly affected to a varying degree in all 
species. Changes include inefficient clearing of ammonia and 
other substances and a fall in the different kinds of blood lipids. 
Because of the striking organelle alterations already mentioned, 
additional subtle functional effects of portal blood deprivation 
are likely and are probably wide ranging (1). 
Historically, many of the changes caused by portacaval shunt 
have been ascribed simply to reduction of total hepatic blood 
flow to which the portal contribution is normally 80%. This 
"flow hypothesis" emphasized the quantity rather than the 
quality of blood nourishing the liver (1). However, studies from 
Denver and elsewhere (1,2) have shown that the quality of por-
tal venous blood is the dominating factor, These investigations 
in animals have been with heterotopic transplants, portacaval 
shunts, split or partial transposition and splanchnic division 
(both of the latter being evaluated with or without alloxan dia-
betes or total pancreatectomy), and partial or complete 
nonhepatic splanchnic evisceration (1). In expressing the results 
of these experiments in practical terms, it was concluded that 
the most favorable condition for portal perfusion was splan-
chnic venous blood which contained normal amounts of en-
dogenous insulin. the least favorable condition was perfusing 
with systemic venous blood. Intermediate in quality was splan-
chnic venous blood that was deficient in endogenous insulin 
but which was rich in other as yet unknown elements. 
Subsequent experiments in dogs with portacaval shunts and 
insulin infused over 4 days into the tied off left portal vein, 
showed that the liver injury produced by portacaval shunting 
could be markedly ameliorated (3). However, the insulin pro-
tection was not complete and this was interpreted as reflecting 
missing ancillary substances that were not being replaced. This 
multifactorial theme has been consistent in all the work from 
Denver on hepatotrophic factors (1,3) . 
Hepatotrophic Factors and Regeneration 
This remains a highly controversial area with conflicting 
results from many laboratories. An important current debate is 
whether the portal hepatotrophic factors act as initiators of re-
generation or whether they merely playa permissive or poten-
tiating role. As reviewed recently, the investigations of Fisher, 
Price, Orloff and Bucher and their collaborators, of the Denver 
group, as well as additional studies by other workers, have 
clearly demonstrated that portal factors influence the regenera-
tive response (1). A recent study has confirmed that gut factors 
play an important role in addition to pancreatic factors. In par-
tially hepatectomized dogs. evisceration with preservation of 
the pancreas caused a greater reduction in hepatic regenerative 
response than occurred after pancreatectomy alone. This has 
further strengthened the original multifactorial hypothesis and 
clearly differentiated pancreatic influences from those originat-
ing in the rest of the intra-abdominal gastrointestinal tract (4). 
None of the above experiments have demonstrated that 
hepatotrophic substances actually initiate regeneration, 
although they clearly affect the regenerative response. 
INITIATION OF REGENERATION 
Portal Factors as Initiators 
Is there any evidence favoring an initiator role for portal 
hepatotrophic factors? The most compelling argument in the 
past has been the well ordered biphasic changes that occur in 
the liver in the hormonally controlled "messenger" compo-
nents, cyclic AMP and adenyl cyclase, prior to and during 
regeneration (1). Various nonhepatic splanchnic eviscerations, 
which have a profound I~dyDerse effect on regeneration, cause 
severe pertubations in these "messenger" components (4), as 
well as in ornithine decarboxylase levels. It remains speculative 
whether these deviations have a cause and effect relationship or 
whether they are merely coincidental to alreJdy initiated regen-
eration. We have an open mind about the possibility that those 
changes that have been noted in the regenerating liver prior to 
the commencement of DNA synthesis (and the subsequent 
increase in mitoses) are merely evidence of an early stage of 
regeneration which has been initiated by some other factor or 
factors. There is no currently available firm evidence supporting 
or denying portal hepatotrophic substances as initiators of re-
generation. Nevertheless, Bucher and her associates at Harvard 
have been examining the possibility of hormone therapy (par-
ticularly insulin and glucagon) for fulminant hepatic failure. 
Non-Portal Factors as Initiators: Liver Factors 
If portal factors prove to only have a permissive or potentiat-
ing role in liver regeneration, what switches on or initiates the 
regenerative response? The important additional and by no 
means contradictory possibility that something in the liver itself 
after partial hepatectomy or liver cell damage contributes to, or 
even initiates, its own regrowth merits careful evaluation. The 
concept of intrinsic hepatic growth control factors has been con-
sidered in the literature for almost 50 ye.:'rs (1). The most con-
vincing early evidence was presented by Blomqvist in 1957 (5). 
He found that liver mash prepared from normal weanling (i.e. 
young growing) rats, and from the already regenerating rem-
nant of adult rat livers after partial hepatectomy, when given 
one-time intraperitoneally to adult rats, caused hepatocyte pro-
liferation which was maximal at 48 hours. On the other hand, 
normal adult liver mash was non-stimulatory (5). This work has 
been extended and confirmed by La Brecque and Pesch (6) 
using a more purified liver extract consisting of the supernatant 
from liver mashes after high speed centrifugation. 
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Alltoradiograpl,y: Number of thymidine labelled hepato-
cytes per 1000 hepatocytes. Cytosol from normal and 24 
hour regenerating livers does not alter the pattern that oc-
curs after portacaval shunt (no treatment Kgro~pFK The 48 
hour and particularly the 72 hour regeneratmg hver cytosol 
has a marked stimulatory effect at two and three days. 
In the meanwhile, evidence was accumulating from both ill 
flit'o and ill !Ii/YO experiments that animJls with regenerating 
liwrs have a circulating plilsma or serum sti~ulatory fact?f E~FK 
tl\e d.lt.) presented above would be cor:'panble with thiS Clf-
pJ.ltory factor having originated in the lIver Itself. it "I~I h.lve recentl y examined the ques_tf~n of a stimulatory fac-
lOr in the liver using a preVIOusly de!:icnbed portacaval sh~nt 
ldd (3) which permitted extracts?f normal and regeneratmg 
liver to bt· introduced into thl' left tied off branch of the portal 
ein .lnd ksted (or rl'glllnal as well as general hepatic effects (7). 
lr~Klndle frel' cytosol extracts from normal dog hve~s and dog 
liver after 70% hepatectomy that had been rege.nerahng ~or 24, 
~ .md 72 hours were infused for 6 hours only mto the tied off 
left portal vein, 4 to 6 hours after constructing a portacaval 
shunt. A stimulatory effect was not present m the cytosol from 
n<lrmal or 24 hour regenerating livers but became demonstrable 
in 48 hour remnants and was highly significant in tissues that 
had been regenerating for 72 hours (Figure 1). It is presumably 
no coincidence that both the full development of extract po-
tency from regenerating liver as well as the full response to it in 
a second animal required 3 days (7), the same time hepatic 
regeneration rcaches a peak after 70% hepatectomy in dogs (8). 
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Cell Size: Cytosol from normal and 24 hour regenerating 
livers does not alter the atrophy that occurs after portacaval 
shunt (no treatment group). The 48 hours and particularly 
the 72 hours regenerating liver cytosol causes reversal of 
these changes between the second and third days. 
Furthermore, both the 48 and 72 hour regenerating extract re-
versed the atrophy usually caused by portacaval shunting in 3 
days (Figure 2) and partially prevented the ultrastructural 
hepatocyte deterioration characteristic of portacaval shunt. It 
was concluded that active liver extracts contained a growth con-
trol factor or factofs which was (were) not insulin or glucagon. 
The brief exposure to the extract shortly after portacaval 
shunt with a delayed regenerative response is suggestive of a 
"switch-on" or initiating mechanism. Further experiments are 
required to confirm and elill-8rate on these findings. If the active 
liver sub~tanceEsF Can be isolated and identified using standard 
biochemical techniques and confirmed to be potent in this and 
other models, a stimulator substance will become available 
which might have important clinical applications. The organ 
and species specificity of the stimulator substance in liver 
cytosol still requires further investigation. 
INHIBITION OF REGENERATION 
Past and recent work has suggested that non-regenerating 
adult liver and serum contain inhibitory growth factors (1). This 
was not confirmed in our recent portacaval shunt infusion 
studies (7); but it was also not excluded, as a greater background 
mitotic activity might be required to detect inhibition. Infusion 
of liver cytosol into an already regenerating liver such as a 40% 
hepatectomy dog model might answer this question, as has 
already been suggested in rat experiments (6). 
CLINICAL IMPLICATIONS 
The most important clinical use for a specific hepatic regener-
ation stimulatory substance might well be in fulminant hepatic 
failure. Saunders and co-workers have pOinted out that the 
ability of liver to regenerate in the setting of fulminant hepatic 
failure has been overemphasized in the past (9). As no major 
breakthrough has been made in the management of this highly 
lethal condition to date, it is hoped that a better understanding 
of the controlling mechanisms of regeneration, including both 
initiators and potentiators, might lead to the development of 
techniques for stimulating regeneration in these patients (1). 
Future therapy with as yet unidentified initiators of regenera-
tion is an exciting possibility. 
The currently available data on the adverse effects of the por-
toprival state created by a portacaval shunt makes completely 
diverting shunt procedures (such as end-to-side portacaval 
shunt) undesirable in managing patients with portal hyperten-
sion. The Warren-Zeppa shunt, which preserves part of the 
portal flow to the liver, is the one procedure that still holds 
promise for the future. Alternatively, we should increasingly 
look for non-shunt procedures, such as periesophageal 
sclerotherapy of varices (10), to manage patients who have bled 
from esophageal varices. 
On the other hand, the normally adverse metabolic effects of 
portacaval shunting have been beneficial for some pa tients with 
glycogen storage disease or in Type II hyperlipidemia (1). Long 
term evaluation of patients so treated is of obvious importance. 
CONCLUSIONS 
The authors current concept is that multifactorial hepato-
trophiC portal substances playa permissive or potentiating role 
in hepatic regeneration, and that the possibility still exists that 
they may actually initiate this process. Although insulin has 
been shown to be the single most important hepatotrophic fac-
tor, other, as yet unidentified, splanchnic factors also playa 
major role. However, the initiator or initiators (or switch-on 
mechanism) of hepatic regeneration is (are) as yet unknown. 
The same applies to the inhibitor or inhibitors (switch-
off mechanism) of hepatic growth. Either or both of these 
mechanisms maintain liver size at a remarkably constant level 
and stimulate regrowth until the normal mass is once again 
attained after removal of part of the liver or after liver cell dam-
age. There is a possibility that a hepatic growth control factor or 
factors originates in the liver itself. 
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CCK is released from the proximal intestine by partly di-
gested proteins and fatty acids8,9, These intraluminal stimu-
lants are teleologically appropriate since they result in secretion 
of pancreatic proteolytic and lipolytic enzymes and the dis-
charge of bile salts from the gallbladder. 
NEURAL CONTROL 
Adrenergic innervation of gallbladder muscle is sparse; most 
of the adrenergic fibers in the human gallbladder are distributed 
to blood vessels. The extent of vagal cholinergic innervation of 
gallbladder smooth muscle has yet to be defined; vagotomy is 
said to decrease nerve fibers in the wall of the gallbladder by 
10%, Cholinergic agonists contract and p-adrenergicagonists 
relax gallbladder smooth muscle but the extent of cholinergic 
and adrenergic control of gallbladder motor activity is uncer-
tain, 
VIP-immunoreactive nerve fibers and cell bodies have re-
cently been demonstrated in muscle a.nd submucosal layers of 
the gallbladder in man and other mammals and appear to reach 
the gallbladder via the vagus nerve. VIP relaxe~ ~allbladder 
muscle and antagonizes the contractile effect of CCK 1. It seems 
reasonable to speculate that VIP and CCK function as the neural 
and hormonal limbs of a peptide system for the control of 
gallbladder motor activity. 
SUMMARY 
Hepatic bile is converted in the gallbladder from an isotonic 
solution of NaCl dnd :\'aHC03 to a concentrated but isotonic 
solution of bile salts. The gallbladder mucosa is a typical leaky 
epithelium with high passive permeability to ions and water. 
The distinctive feature of active ion transport by the gallbladder 
is the presence of an electrically neutral coupled NaCl influx 
process at the luminal membrane which insures a one-to-one 
absorption of Na+ and Cl- and is partly responsible for the 
absent or low transepithelial potential difference. Gallbladder 
contraction and choledochal relaxation are under the control of 
a peptide hormone, cholecystokinin. The extent of neural con-
trol of gallbladder motor function is uncertain .. 
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